Vor Biopharma Inc. (VOR) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Core Insights - Vor Therapeutics is developing telitacicept, a BAFF/APRIL inhibitor, which has shown promising data in Phase III trials for generalized Myasthenia Gravis (gMG) and Sjögren's syndrome [2] Group 1: Clinical Development - The Phase III data for gMG is expected to be released midyear, while the first patient for the global Phase III study of Sjögren's is anticipated by the end of the first half of the year [2] - The data for gMG appears promising, and there is significant excitement surrounding the potential of telitacicept in treating Sjögren's syndrome, which is considered a large unmet medical need [2]